Our research primarily focuses on iPS reprogramming, direct cell conversion, and patient-specific stem cell generation. The goal is to develop innovative treatments for currently challenging diseases and degenerative conditions. These innovative approaches also hold potential for application in drug screening and toxicity testing.

​

In particular, our research leverages the concept of "Organoids" Organoids are 3D cell structures that closely resemble the structure and function of real tissues. Through organoid models, we can simulate and study disease progression in an environment closely resembling human tissue. This enables us to unravel disease mechanisms and explore better treatment strategies.

​

Our research is conducted in close collaboration with the Max Planck Institute for Molecular Biomedicine in Münster, Germany. This collaboration aims to maximize research synergy and establish a world-class stem cell research group. Through these efforts, we anticipate advancing the understanding of various diseases and fostering innovation in treatment methods.